Spasticity

Neurology·MeSH: Muscle Spasticity

Prevalence

26.5 / 100K

Incidence

0.8 / 100K/yr

26 drugs in development·13 companies·5 clinical trials

Drug Pipeline by Phase

Approved(7)

Drug	Company
baclofen	MAIA Biotechnology, Inc. (MAIA)
baclofen	Impax Laboratories, LLC (IPXL)
baclofen	ANI PHARMACEUTICALS INC (ANIP)
cannabis	One World Products, Inc. (OWPC)
dysport	NEXIEN BIOPHARMA, INC. (NXEN)
iovera°	Pacira BioSciences, Inc. (PCRX)
tizanidine	Aptinyx Inc. (APTX)

Phase 3(7)

Drug	Company
arbaclofen	RVL Pharmaceuticals plc (RVLP)
arbaclofen er	RVL Pharmaceuticals plc (RVLP)
Dysport	Valneva SE (VALN)
nabiximols	GW PHARMACEUTICALS PLC (GWPH)
NT 201	Revance Therapeutics, Inc. (RVNC)
recombinant adamts13	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
recombinant botulinum toxin type a	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(1)

Drug	Company
IPN10200	Valneva SE (VALN)

Phase 1(5)

Drug	Company
Sequence 1	Revance Therapeutics, Inc. (RVNC)
Sequence 2	Revance Therapeutics, Inc. (RVNC)
Sequence 3	Revance Therapeutics, Inc. (RVNC)
Sequence 4	Revance Therapeutics, Inc. (RVNC)
Sequence 5	Revance Therapeutics, Inc. (RVNC)

Preclinical(2)

Drug	Company
abp-450	AEON Biopharma, Inc. (AEON)
cannabis-derived products	One World Products, Inc. (OWPC)

Phase 4(4)

Drug	Company
AboBoNT-A	Revance Therapeutics, Inc. (RVNC)
Botulinum Neurotoxin Type A	Revance Therapeutics, Inc. (RVNC)
OnaBoNT-A	Revance Therapeutics, Inc. (RVNC)
Recombinant Botulinum Toxin Type A for injection	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 26 drugs in development for Spasticity across 13 companies.

There are 5 clinical trials targeting Spasticity tracked by BioSniper.

The estimated prevalence of Spasticity is approximately 26.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.